Engineers Gate Manager’s Allogene Therapeutics ALLO Stock Holding History

Engineers Gate Manager’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$205K	Sell	98,511 -7,404	-7%	-$16.3K	﹤0.01%	1958
2026 Q1	$258K	Buy	+105,915	New	+$212K	﹤0.01%	1787
2025 Q4	–	Sell	-36,446	Closed	-$45.2K	–	2073
2025 Q3	$45.2K	Buy	36,446 +3,981	+12%	+$4.75K	﹤0.01%	2066
2025 Q2	$36.7K	Buy	+32,465	New	+$43.1K	﹤0.01%	2071
2024 Q4	–	Sell	-47,773	Closed	-$134K	–	2197
2024 Q3	$134K	Buy	+47,773	New	+$127K	﹤0.01%	1882
2023 Q3	–	Sell	-95,746	Closed	-$476K	–	1768
2023 Q2	$476K	Sell	95,746 -5,619	-6%	-$30.4K	0.02%	1067
2023 Q1	$501K	Sell	101,365 -33,714	-25%	-$216K	0.02%	975
2022 Q4	$850K	Buy	135,079 +86,935	+181%	+$805K	0.05%	579
2022 Q3	$520K	Buy	+48,144	New	+$654K	0.03%	789
2022 Q1	–	Sell	-20,105	Closed	-$300K	–	1816
2021 Q4	$300K	Buy	+20,105	New	+$355K	0.01%	1406
2021 Q3	–	Sell	-21,980	Closed	-$573K	–	1608
2021 Q2	$573K	Buy	21,980 +12,150	+124%	+$346K	0.04%	754
2021 Q1	$347K	Buy	+9,830	New	+$332K	0.02%	1225

Other funds holding ALLO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Engineers Gate Manager's ALLO Position: Q2 2026 in Review

Engineers Gate Manager reduced its Allogene Therapeutics (ALLO) stake by 7% in Q2 2026, selling an estimated $16.3K and leaving 98,511 shares worth $205K. The position accounts for ﹤0.01% of the portfolio, ranked #1958.

Engineers Gate Manager first reported a position in ALLO in Q1 2021 and has held it in 12 quarters since. The position peaked at $850K in Q4 2022. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

Engineers Gate Manager held 98,511 shares of Allogene Therapeutics worth $205K as of Q2 2026.
Engineers Gate Manager sold 7,404 Allogene Therapeutics shares in Q2 2026, an estimated $16.3K.
Allogene Therapeutics made up ﹤0.01% of Engineers Gate Manager's portfolio in Q2 2026, its #1958 holding.
Engineers Gate Manager first reported a position in Allogene Therapeutics in Q1 2021 and has held it in 12 quarters since.
Engineers Gate Manager's Allogene Therapeutics position peaked at $850K in Q4 2022.
209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.